Introduction
The peripheral nervous system (PNS) is exposed to a variety of damages, from mechanical traumas to autoimmune or neurotoxic attacks. In humans, peripheral nerve injuries may also derive from surgical resections like those occurring during excision of tumors. For its essential roles in physiology and survival, the PNS has retained throughout evolution the capability to regenerate. [1] [2] [3] [4] [5] Nevertheless, several factors, including injury type, its anatomical location, and the extent of associated inflammation, can limit the extent of the repair process. The mechanisms and players of peripheral nerve regeneration are intensively investigated, as the molecular and cellular understanding of the regeneration process will lead to the discovery of chemical and biological molecules to improve rehabilitation of PNS neurons after accidents. In addition, there is the possibility that the same actors may be beneficial for the central nervous system, where regeneration is poor.
Recently, we found that the chemokine CXCL12a potently promotes the recovery of the neuromuscular ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. junction (NMJ) activity after degeneration of the motor axon terminal. 6 In this process, CXCL12a is synthetized and released by perisynaptic Schwann Cells (SC), and acts via the CXCR4 receptor re-expressed on the tip of the regenerating motor axon terminal. 6 CXCL12a (also known as SDF-1) is a secreted chemokine discovered as a growth factor for the bone marrow pre-B cells, 7, 8 and later shown to be involved in the development of various regions of the central nervous system. [9] [10] [11] As other chemokines, it acts via a G protein coupled receptor, dubbed CXCR4, forming a signaling axis involved in a variety of responses in the immune and nervous systems. [12] [13] [14] [15] [16] [17] [18] Given its nature as modulator of the immune system, CXCL12a is susceptible to posttranslational modifications and hydrolysis in body fluids that block/attenuate its biological activity, bioavailability and half-life, resulting in poor pharmacokinetics properties. 19 In addition, CXCL12a structure consists of 93 amino acids, 5 cysteines, and 2 disulfide bridges which makes its production via recombinant methods complicated and very costly.
On the other hand, as CXCR4 is the co-receptor driving the entry of HIV into human immune cells, in addition to its involvement in a variety of regulatory and modulatory activities of the immune and nervous systems, 15, 20 an intensive search for CXCR4 antagonists and agonists with favorable pharmacokinetics is ongoing. A novel group of CXCR4 ligands was recently identified and, among them, a new molecule, dubbed NUCC-390, displayed the best capability to activate the receptor in a cell line. 21 Here, we describe the finding that the expression of CXCL12a and CXCR4 increases at the site of sciatic nerve crush, and we report compelling evidence that the stimulation of CXCR4 with the agonist NUCC-390 accelerates neurotransmission rescue mainly by promoting axonal elongation.
Materials and Methods
Reagents NUCC-390 synthesis was performed as previously described. 22 AMD3100, a strong CXCR4 antagonist, was from Abcam (120718). Cytosine b-D-arabinofuranoside (C6645), DNase I (DN25), poly-L-lysine (P1274), laminin (L2020), and trypsin (T4799) were from Sigma Aldrich. µ-conotoxin GIIIB was from Alomone. Primary antibodies: b 3 -tubulin (302302, Synaptic System), NF (ab4680, Abcam), CXCR4 (ab1670, Abcam), GAP43 (ab75810, Abcam), CXCL12a (Cell Signaling, BK3740S). Secondary antibodies were from Thermo Scientific.
Animals and Ethical statement
C57BL/6 mice expressing cytosolic GFP under the plp promoter 23 were kindly provided by Dr. W. Macklin (Aurora, Colorado) and Dr. T. Misgeld (Munchen, Germany). They were used in imaging experiments. CD1 mice were from the local animal facility, and were employed for electrophysiological recordings. Animal care and experimental procedures were performed in accordance with National laws and policies (D.L. n. 26, March 14, 2014) , with the guidelines established by the European Community Council Directive (2010/63/EU), and were approved by the local authority veterinary services.
Sciatic nerve injury, electrophysiology, and immunostaining
Six-eight week-old CD1 or C57BL6-J plp-GFP mice were anesthetized with xylazine (48 mg/kg) and zoletil (16 mg/ kg) via i.p. injection. The sciatic nerve was exposed and crushed or cut as described. 24, 25 Briefly, an incision was made in the skin that is gently dissected from the underlying musculature. Then the fascial plane between the gluteus maximus and the anterior head of the biceps femoris was open revealing the sciatic nerve. The nerve was then gently freed from the surrounding connective tissue, and cut using small surgical scissor or, alternatively, placed on the bottom jaw of a super-fine haemostatic forceps for the crush. The nerve was crushed once for 40 sec with three clicks of the haemostatic forceps predipped in powdered carbon, used to mark the crush site. Finally, the gluteal musculature was re-opposed and the skin sutured using 6-0 braided silk, nonabsorbable sutures (ETHL-CON2 biological instruments, 8697). After surgery, mice were i.p. injected with the indicated treatments: NUCC-390 26 mg/kg (daily), or AMD3100 4 mg/kg (twice daily), or AMD3100 plus NUCC-390, or 100 µg neutralizing anti-CXCL12a antibody (weekly, R&D MAB310). At indicated time points compound muscle action potentials (CMAP) were recorded in gastrocnemius muscles of anesthetized mice upon supramaximal stimulation of the sciatic nerve (15 V, 4 ms and 0.5 Hz), approximately 0.5 mm below the sciatic notch. Electromyographic signals were amplified with a GrassP6 Amplifier (Grass, USA), fed to a PC using an A/D interface (BNC-2110, NI, USA). Traces were recorded with WinEDR, and analyzed using pClamp10. CMAP values from one hind limb muscle were normalized to those from the contralateral one of the same mouse, which received the same treatment (i.p. injection of either the agonist, or the antagonist, or of the neutralizing antibodies), thus making the result independent of muscle fiber dimensions.
For immunostaining, sciatic nerves from C57BL6-J plp-GFP mice were fixed in 4% paraformaldehyde for 10 min at RT, quenched in 50 mmol/L NH 4 Cl, and saturated in blocking solution containing 0.5% Triton X-100. Incubation with antibodies was performed for >48 h in blocking solution. After washings and incubation with secondary antibodies, images were collected with a SP5 confocal microscope (Leica, Germany). Where indicated, whole mount staining was performed as in. 26 
Neuronal cultures and axon length quantification
Cultures of spinal cord motor neurons (SCMNs) were prepared as previously described. 27 After plating, neurons were exposed for 24 h to the indicated concentrations of either NUCC-390, or AMD3100, or their combination in culture medium. Cells were fixed for 10 min (4% paraformaldehyde), stained for b 3 -tubulin, and examined by epifluorescence microscopy (Leica DMIRE2). Axon length was quantified with NeuronJ (ImageJ).
Statistical analysis
A group size of seven mice allowed to detect a difference in the mean values between groups with a power of 80% and a statistical significance of 5% in in vivo experiments. At least three independent replicates for cell culture experiments were conducted in blind. Data are expressed as mean AE SEM. GraphPad Prism software was used for all statistical analyses. Statistical significance was calculated by ANOVA with Tukey post-test, or two-tailed unpaired Student's t-test depending on the number of groups analysed. Data were considered statistically different when *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Results
The CXCR4 receptor and its ligand CXCL12a are strongly expressed in the sciatic nerve after crush
We tested the expression of CXCL12a and CXCR4 after axonal damage in a well-established model of traumatic neuronal injury consisting in the compression (crush) of the sciatic nerve. 5, 24 The crush causes interruption of many axons, mostly of myelinated ones, with preservation of Schwann cells (SC) and the basal lamina (BL), which are essential for nerve regeneration to take place. Figure 1 shows the expression of CXCR4 in longitudinal (A-B) and cross-sections (C) collected consecutively (slices of 20 µm thickness each) in control sciatic nerves or over the lesion site in after crush. CXCR4 is barely detectable in noninjured nerves, but its signal strongly increases in the axonal compartment after damage where it co-localizes with neurofilament (NF). Neurons negative for CXCR4 are likely to be those neurons whose axons were spared by the crush, or that were already beyond the regeneration front. Also CXCL12a expression increases in the crushed area 3 and 7 days after injury (D), but in this case the signal mainly colocalizes with GFP, suggesting expression mainly by SC. However, given the known biological activities of CXCL12a and the inflammatory reaction triggered by nerve compression, it is possible that inflammatory cells recruited in the damaged area, as well as resident cells such as endoneural, endothelial cells and fibroblasts, do express CXCL12a, thus explaining the staining pattern at 3 days post crush ( Fig. 1 panel D) . We did not pursue further this aspect as we mainly focused on the signaling axis formed by CXCL12a and CXCR4 expressed by SC and neurons, respectively, following axonal damage. The comparison of the crushed nerves at 3 and 7 days indicates that the increase in CXCL12a expression induced by the injury is transient, with the chemokine almost disappearing after 7 days. At variance, the expression of CXCR4 is more persistent, a finding that speaks in favor of a therapeutic use of a CXCR4 agonist.
The CXCL12a-CXCR4 axis is involved in the functional recovery upon crush
To assess the functional role of the CXCL12a-CXCR4 axis in the recovery from nerve injury we measured the compound muscle action potential (CMAP) in gastrocnemius muscles of crushed CD1 mice treated either with a specific antibody neutralizing CXCL12a, or with AMD3100, a specific CXCR4 antagonist, as schematically indicated in Figure 2A . Both treatments cause a strong delay in neurotransmission recovery. This is quantified in panel B of Figure 2 , which reports the CMAP areas of injured nerves (2 weeks after crush), showing that the inhibition of either components of the axis delays regeneration.
The CXCR4 agonist NUCC-390 promotes neuromuscular recovery after sciatic nerve crush
The finding that CXCL12a is expressed for a limited time period after nerve injury (Fig. 1D) suggests that it may function as initiator of the repair process. At the same time, as CXCR4 expression persists longer (Fig. 1C) , even when its ligand is no more detectable, we reasoned that a prolonged stimulation of the receptor might foster regeneration. As CXCL12a displays a very poor pharmacokinetics in vivo, 19 we treated crushed mice with the chemical compound NUCC-390, which was recently shown to act similarly to CXCL12a in a cell culture system. 21 CMAP areas measured in gastrocnemius muscles 7, 14, and 28 days after injury clearly indicate that NUCC-390 is a good promoter of the functional recovery of the sciatic nerve after crush (Fig. 2D-E) . The accelerated recovery of neurotransmission by NUCC-390 is also indicated by the faster disappearance of the multiple peaks beside the main biphasic shape in the CMAP trace, indicative of a synchronous stimulation of the muscle fibers upon electrical stimulation of the entire nerve. Such a pharmacological effect arises from the specific interaction of NUCC-390 with CXCR4, as it is prevented by AMD3100, a selective antagonist of the CXCR4 receptor (Fig. 2F) . These results suggest that NUCC-390 holds a great potential as therapeutics for damaged peripheral nerves.
NUCC-390 stimulates axonal elongation
By using an in vitro system consisting of primary cultures of spinal cord motor neurons (SCMNs) we found that NUCC-390 induces elongation of motor axons (Fig. 3A,B) , and that this activity is mediated by CXCR4, being it blocked by AMD3100 (Fig. 3C,D) .
The axonal elongation activity of NUCC-390 is displayed also in vivo after nerve transection (an injury that cuts both axons and BL, making regeneration incomplete) as indicated by the evident staining of GAP43, a biochemical marker of active axonal re-growth ( Fig. 3E ). 28 NUCC-390 treatment increases the density of axons in active regrowth in the proximal side, and the number of axons entering the bridge area. On the contrary, AMD3100 prevents the pharmacological effect of NUCC-390, by reducing both the density and the number of GAP43-positive axons entering the bridge segment connecting the distal and the proximal stumps of the nerve. This result confirms that NUCC-390 action on axonal regeneration takes place via CXCR4.
Discussion
The major findings of the present work are the following: (i) an injury to the sciatic nerve triggers the expression of the signaling axis CXCL12a-CXCR4 at the damaged site; (ii) this axis is functionally involved in nerve regeneration because specific inhibition of both components delays the recovery of neuromuscular function; (iii) the CXCR4 agonist NUCC-390 promotes the functional rescue of peripheral nerves by stimulating motor axon elongation. The latter activity, shared by CXCL12a (the natural CXCR4 ligand) and NUCC-390 (CXCR4 agonist), is suggested by the in vitro experiments with cultured motor neurons, by the in vivo effects on CMAP rescue, and by the imaging with specific markers. However, one cannot exclude that the in vivo effects of CXCL12a and NUCC-390 may also result from still unknown activities or signaling mediated by CXCR4 in the neuronal cell body within ganglia and in the ventral horn of the spinal cord.
The in vivo activity of NUCC-390 described here holds a great potential translational value. In fact, given the ongoing intense research for novel therapies for injured peripheral neurons, 29, 30 these results have relevant clinical implications, as they indicate NUCC-390 as a potential pro-regenerative drug to be tested in different animal models of PNS disorders. We recently found that NUCC-390 strongly promotes the functional recovery of motor nerve terminals after the acute degeneration induced by a-latrotoxin at the neuromuscular junction, 22 a model that recapitulates several aspects of autoimmune neuropathies caused by auto-antibodies against peripheral axon antigens. 31 In addition, NUCC-390 activity could be tested in neurodegenerative conditions, like amyotrophic lateral sclerosis, where fostering regenerative programs may help in slowing down disease progression. If positive results will arise from these studies, NUCC-390 would become a strong candidate therapeutics to be evaluated in human peripheral neurotraumas, neuropathies, and neuromuscular disorders.
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